Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing data science and human science together to advance human health and support the pharmaceutical industry from clinical trials to commercialization.
Learn MoreConnecting with powerful, evidence-based market insights to drive agile thinking, uncover growth potential, and gain competitive advantage in this fast-moving consumer health market.
LEARN MOREEmpowering to orchestrate operations across the entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.
Learn moreWorking across the health system to address key barriers to deliver high-quality, cost-effective care while improving health outcomes using our data-driven and population-centric solutions.
LEARN MOREDelivering a wide range of consulting and technology solutions to support healthcare stakeholders to drive operational efficiency, enhance quality of patient care, and improve systemic outcomes.
learn moreClinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.
Learn MoreHarness the power of real-world data and insights to demonstrate value-driven evidence and outcomes to meet stakeholder needs across the healthcare ecosystem and to propel healthcare forward.
LEARN MOREPharmaceutical market data and information assets that provide actionable data points to help organizations make intelligent connections and drive healthcare forward.
LEARN MOREPrimary Intelligence integrates purpose-built and syndicated research solutions with our wide range of data assets, research methodologies, advanced analytics, and deep domain expertise, generating quality insights for our clients.
LEARN MORETrusted advisor and partner to global healthcare organisations, solving the most significant business challenges through extensive healthcare expertise.
LEARN MOREOptimize commercial success by leveraging our comprehensive outsourced expertise to accelerate time-to-market.
LEARN MOREA single window solution provider to support pharmaco’s design, deploy technology and services that help increase access to medicine and improve treatment adherence.
LEARN MOREConnected Intelligence™, digital insights, data analytics and advanced technology to power smarter decision-making to enable better patient outcomes and improved business results.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific.
Learn MoreExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
Discover Insights"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.
Read The Latest Issue"Unlocking the Future of Consumer Health: A Special Focus on Senior Consumers
Learn MoreImproving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
Search JobsThe concepts and value of Real World Evidence (RWE) are well-established, but RWE evolves as the data sources available expand. There are ‘conventional’ sources such as electronic health records, patient registries, and national claim databases; and ‘newer’ data sources such as mobile apps, wearables and social media. Digital and technology are at the forefront of the healthcare industry right now, as the solution to many of the challenges rising from the COVID-19 pandemic. Medical Technology (MedTech) is at the centre of the ‘Internet of Medical Things’ data production, whether as Digital Therapeutics (DTx) or in any given hospital with patients connected to multiple devices. The use of RWE for MedTech is receiving more attention, but the application is still relatively limited.
In many APAC countries, there are no specific MedTech requirements or guidelines on the use of RWE for regulatory approval, HTA or reimbursement. RWE continues to be perceived as “a nice to have” or “supportive” evidence. RWE can be used to address common challenges, such as the evidence gap from being unable to conduct randomized control trials (RCT). RWE can be used to justify the reimbursement price of new products, mitigate the risk of delayed product launches and strengthen product value proposition. Nevertheless, I frequently hear from MedTech players: “where do we begin?”. Here are steps to be considered:
Many companies have had to adapt research operation approaches due to the impact of COVID-19. Remote monitoring, online data collection, virtual investigator meetings, have been demonstrated as useful approaches. These will become the “new normal” practice for RWE in the future and will further add to the huge amounts of RWD the healthcare ecosystem generates.
Preparing for RWE requires early and sustained commitment, with efforts starting at least 1-2 years before launch and reimbursement. New challenges will constantly arise in healthcare and the need to drive human health forward will continue. The need to draw insights from RWE will only increase.
Authors:
Sirinthip Petcharapiruch, Principal, Real World Solutions, Asia Pacific
Ruthie Burr, Consultant, Strategic Marketing and Business Development, Asia Pacific
For more information, please feel free to contact us.